Inactivation of Hepatic Foxo1 by Insulin Signaling Is Required for Adaptive Nutrient Homeostasis and Endocrine Growth Regulation

Cell Metabolism

Volumn 8, Issue 1, 2008, Pages 65-76

  Dong, Xiaocheng C ^a   Copps, Kyle D ^a   Guo, Shaodong ^a   Li, Yedan ^a   Kollipara, Ramya ^b   DePinho, Ronald A ^b   White, Morris F ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Belfer Institute for Innovative Cancer Science   (United States)

Author keywords

HUMDISEASE

Indexed keywords

GLUCOKINASE; GLUCOSE; GROWTH HORMONE RELEASING FACTOR; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR FKHR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY GROWTH; BODY SIZE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE SEVERITY; FEEDING; GENE DELETION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GROWTH REGULATION; HYPERGLYCEMIA; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIVER PARENCHYMA; METABOLIC DISORDER; MOUSE; NONHUMAN; NUTRIENT DYNAMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE SPECIFICITY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ENDOCRINE GLANDS; FOOD; FORKHEAD TRANSCRIPTION FACTORS; GROWTH; HOMEOSTASIS; INSULIN; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; PHOSPHOPROTEINS; SIGNAL TRANSDUCTION;

MUS;

EID: 45549090182     PISSN: 15504131     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmet.2008.06.006     Document Type: Article

References (49)

1. Altomonte J., Richter A., Harbaran S., Suriawinata J., Nakae J., Thung S.N., Meseck M., Accili D., and Dong H. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E718-E728
2. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., and Maratos-Flier E. Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARalpha and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States. Cell Metab. 5 (2007) 426-437
3. Barthel A., Schmoll D., and Unterman T.G. FoxO proteins in insulin action and metabolism. Trends Endocrinol. Metab. 16 (2005) 183-189
4. Biddinger S.B., Hernandez-Ono A., Rask-Madsen C., Haas J.T., Aleman J.O., Suzuki R., Scapa E.F., Agarwal C., Carey M.C., Stephanopoulos G., et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 7 (2008) 125-134
5. Brown M.S., and Goldstein J.L. Selective versus Total Insulin Resistance: A Pathogenic Paradox. Cell Metab. 7 (2008) 95-96
6. Canettieri G., Koo S.H., Berdeaux R., Heredia J., Hedrick S., Zhang X., and Montminy M. Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab. 2 (2005) 331-338
7. Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw III E.B., Kaestner K.H., Bartolomei M.S., Shulman G.I., and Birnbaum M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292 (2001) 1728-1731
8. Daitoku H., Yamagata K., Matsuzaki H., Hatta M., and Fukamizu A. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 52 (2003) 642-649
9. Dann S.G., Selvaraj A., and Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med. 13 (2007) 252-259
10. Dentin R., Liu Y., Koo S.H., Hedrick S., Vargas T., Heredia J., Yates III J., and Montminy M. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449 (2007) 366-369
11. Dong X., Park S., Lin X., Copps K., Yi X., and White M.F. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J. Clin. Invest. 116 (2006) 101-114
12. Gershman B., Puig O., Hang L., Peitzsch R.M., Tatar M., and Garofalo R.S. High-resolution dynamics of the transcriptional response to nutrition in Drosophila: a key role for dFOXO. Physiol. Genomics 29 (2007) 24-34
13. Gibbons G.F. Regulation of fatty acid and cholesterol synthesis: co-operation or competition?. Prog. Lipid Res. 42 (2003) 479-497
14. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., and Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11 (2006) 859-871
15. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109 (2002) 1125-1131
16. Huang J., Dibble C.C., Matsuzaki M., and Manning B.D. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol. 28 (2008) 4104-4115
17. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., and Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006) 125-137
18. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
19. Koo S.H., Flechner L., Qi L., Zhang X., Screaton R.A., Jeffries S., Hedrick S., Xu W., Boussouar F., Brindle P., et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437 (2005) 1109-1111
20. Lahuna O., Rastegar M., Maiter D., Thissen J.P., Lemaigre F.P., and Rousseau G.G. Involvement of STAT5 (signal transducer and activator of transcription 5) and HNF-4 (hepatocyte nuclear factor 4) in the transcriptional control of the hnf6 gene by growth hormone. Mol. Endocrinol. 14 (2000) 285-294
21. Lannoy V.J., Decaux J.F., Pierreux C.E., Lemaigre F.P., and Rousseau G.G. Liver glucokinase gene expression is controlled by the onecut transcription factor hepatocyte nuclear factor-6. Diabetologia 45 (2002) 1136-1141
22. Le R.D., Bondy C., Yakar S., Liu J.L., and Butler A. The somatomedin hypothesis: 2001. Endocr. Rev. 22 (2001) 53-74
23. Lin X., Taguchi A., Park S., Kushner J.A., Li F., Li Y., and White M.F. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J. Clin. Invest. 114 (2004) 908-916
24. Manning B.D., and Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 129 (2007) 1261-1274
25. Matsumoto M., Han S., Kitamura T., and Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J. Clin. Invest. 116 (2006) 2464-2472
26. Matsumoto M., Pocai A., Rossetti L., DePinho R.A., and Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor foxo1 in liver. Cell Metab. 6 (2007) 208-216
27. Michael M.D., Kulkarni R.N., Postic C., Previs S.F., Shulman G.I., Magnuson M.A., and Kahn C.R. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6 (2000) 87-97
28. Mora A., Lipina C., Tronche F., Sutherland C., and Alessi D.R. Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. Biochem. J. 385 (2005) 639-648
29. Mounier C., and Posner B.I. Transcriptional regulation by insulin: from the receptor to the gene. Can. J. Physiol. Pharmacol. 84 (2006) 713-724
30. Murphy C.T., McCarroll S.A., Bargmann C.I., Fraser A., Kamath R.S., Ahringer J., Li H., and Kenyon C. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424 (2003) 277-283
31. Nakae J., Biggs III W.H., Kitamura T., Cavenee W.K., Wright C.V., Arden K.C., and Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat. Genet. 32 (2002) 245-253
32. Nakae J., Kitamura T., Silver D.L., and Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 108 (2001) 1359-1367
33. Okamoto Y., Ogawa W., Nishizawa A., Inoue H., Teshigawara K., Kinoshita S., Matsuki Y., Watanabe E., Hiramatsu R., Sakaue H., et al. Restoration of Glucokinase Expression in the Liver Normalizes Postprandial Glucose Disposal in Mice With Hepatic Deficiency of PDK1. Diabetes 56 (2007) 1000-1009
34. Paik J.H., Kollipara R., Chu G., Ji H., Xiao Y., Ding Z., Miao L., Tothova Z., Horner J.W., Carrasco D.R., et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128 (2007) 309-323
35. Pierreux C.E., Stafford J., Demonte D., Scott D.K., Vandenhaute J., O'Brien R.M., Granner D.K., Rousseau G.G., and Lemaigre F.P. Antiglucocorticoid activity of hepatocyte nuclear factor-6. Proc. Natl. Acad. Sci. USA 96 (1999) 8961-8966
36. Puigserver P., Rhee J., Donovan J., Walkey C.J., Yoon J.C., Oriente F., Kitamura Y., Altomonte J., Dong H., Accili D., and Spiegelman B.M. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423 (2003) 550-555
37. Rausa F., Samadani U., Ye H., Lim L., Fletcher C.F., Jenkins N.A., Copeland N.G., and Costa R.H. The cut-homeodomain transcriptional activator HNF-6 is coexpressed with its target gene HNF-3 beta in the developing murine liver and pancreas. Dev. Biol. 192 (1997) 228-246
38. Samuel V.T., Choi C.S., Phillips T.G., Romanelli A.J., Geisler J.G., Bhanot S., McKay R., Monia B., Shutter J.R., Lindberg R.A., et al. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55 (2006) 2042-2050
39. Schilling M.M., Oeser J.K., Boustead J.N., Flemming B.P., and O'Brien R.M. Gluconeogenesis: re-evaluating the FOXO1-PGC-1alpha connection. Nature 443 (2006) E10-E11
40. Shachter N.S., Ebara T., Ramakrishnan R., Steiner G., Breslow J.L., Ginsberg H.N., and Smith J.D. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J. Clin. Invest. 98 (1996) 846-855
41. Sharov A.A., Dudekula D.B., and Ko M.S. A web-based tool for principal component and significance analysis of microarray data. Bioinformatics 21 (2005) 2548-2549
42. Taniguchi C.M., Ueki K., and Kahn C.R. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J. Clin. Invest. 115 (2005) 718-727
43. van der Horst A., and Burgering B.M. Stressing the role of FoxO proteins in lifespan and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 440-450
44. Wolfrum C., Asilmaz E., Luca E., Friedman J.M., and Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 432 (2004) 1027-1032
45. Wu J., Tseng Y.D., Xu C.F., Neubert T.A., White M.F., and Hubbard S.R. Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2. Nat. Struct. Mol. Biol. 15 (2008) 251-258
46. Yoon J.C., Puigserver P., Chen G., Donovan J., Wu Z., Rhee J., Adelmant G., Stafford J., Kahn C.R., Granner D.K., et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413 (2001) 131-138
47. Zhang L., Rubins N.E., Ahima R.S., Greenbaum L.E., and Kaestner K.H. Foxa2 integrates the transcriptional response of the hepatocyte to fasting. Cell Metab. 2 (2005) 141-148
48. Zhang W., Patil S., Chauhan B., Guo S., Powell D.R., Le J., Klotsas A., Matika R., Xiao X., Franks R., et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 281 (2006) 10105-10117
49. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787